Chembio Diagnostics (NASDAQ:CEMI) issued its earnings results on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.10), Fidelity Earnings reports. Chembio Diagnostics had a negative return on equity of 26.91% and a negative net margin of 16.54%.
Shares of NASDAQ CEMI traded down $0.47 during midday trading on Friday, reaching $6.78. The stock had a trading volume of 727,900 shares, compared to its average volume of 40,565. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.53 and a quick ratio of 2.58. Chembio Diagnostics has a 12-month low of $6.44 and a 12-month high of $11.55. The stock has a market cap of $101.23 million, a PE ratio of -13.21 and a beta of 1.46.
In other Chembio Diagnostics news, insider Robert Passas acquired 15,000 shares of the stock in a transaction on Monday, November 5th. The stock was acquired at an average price of $6.75 per share, for a total transaction of $101,250.00. Following the completion of the transaction, the insider now directly owns 15,000 shares of the company’s stock, valued at $101,250. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.65% of the stock is currently owned by corporate insiders.
Chembio Diagnostics Company Profile
Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.
Further Reading: Fundamental Analysis and Individual Investors
Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.